NCT07033533View on ClinicalTrials.gov

Allopurinol and Pathogenesis of Cirrhosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Cirrhoses, Liver
Interventions
DRUG

Allopurinol Tablet

allopurinol 300

DRUG

Placebo

placebo tablet

Trial Locations (1)

Unknown

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT07033533 - Allopurinol and Pathogenesis of Cirrhosis | Biotech Hunter | Biotech Hunter